Skip to main content

Advertisement

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms

Fig. 1

ZT55 is a biochemically selective JAK2 inhibitor. (a) Chemical structure and formula weight of ZT55. (b) The selective activity (IC50) of ZT55 against recombinant JAK family members using in vitro kinase assay (n = 6). (c) The curve of JAK2 kinase activity treated by ZT55 in vitro. (d) and (e) Molecular model depicting docking of ZT55 in the JAK2 ATP pocket. Key inhibitor-protein interactions, including two hydrogen bonds, three carbon hydrogen bonds, four halogen bonds, and four Pi-alkyl bonds are shown

Back to article page